Investigating the Next Wave of Innovation to Help People with Hemophilia
Watch below.
Hiding in Plain Sight: The Racial Toll of Lyme Disease
Lyme disease is the most common vector-borne illness in the United States. New research indicates that people of color are more likely to develop more severe Lyme disease.
Hiding in Plain Sight: The Racial Toll of Lyme Disease
Lyme disease is the most common vector-borne illness in the United States. New research indicates that people of color are more likely to develop more severe Lyme disease.
Pursuing the Next Breakthrough in Cancer Cachexia
Cachexia, a complex wasting syndrome, impacts an estimated 9 million people worldwide. Currently, there are no FDA-approved treatments targeting its underlying cause.
Pursuing the Next Breakthrough in Cancer Cachexia
Cachexia, a complex wasting syndrome, impacts an estimated 9 million people worldwide. Currently, there are no FDA-approved treatments targeting its underlying cause.
Developing a Path Forward in Cancer Cachexia
Across disciplines, therapeutic areas, and even continents, Pfizer scientists have been working to advance understanding of – and potential treatments for – cachexia, a complex metabolic condition associated with certain chronic conditions.
Developing a Path Forward in Cancer Cachexia
Across disciplines, therapeutic areas, and even continents, Pfizer scientists have been working to advance understanding of – and potential treatments for – cachexia, a complex metabolic condition associated with certain chronic conditions.
Bridging Global Gaps in Hemophilia Care
Pfizer is proud of its commitment to advancing hemophilia care for more than 40 years, dating back to the introduction of recombinant therapies.
Bridging Global Gaps in Hemophilia Care
Pfizer is proud of its commitment to advancing hemophilia care for more than 40 years, dating back to the introduction of recombinant therapies.
In Search of a New Hemophilia Treatment
Despite significant advancements in hemophilia treatments over the past several decades, balancing management of the disorder while maintaining regular day-to-day activities remains a challenge.
In Search of a New Hemophilia Treatment
Despite significant advancements in hemophilia treatments over the past several decades, balancing management of the disorder while maintaining regular day-to-day activities remains a challenge.
Hiding in Plain Sight: The Racial Toll of Lyme Disease
Lyme disease is the most common vector-borne illness in the United States. New research indicates that people of color are more likely to develop more severe Lyme disease.
Hiding in Plain Sight: The Racial Toll of Lyme Disease
Lyme disease is the most common vector-borne illness in the United States. New research indicates that people of color are more likely to develop more severe Lyme disease.
Pursuing the Next Breakthrough in Cancer Cachexia
Cachexia, a complex wasting syndrome, impacts an estimated 9 million people worldwide. Currently, there are no FDA-approved treatments targeting its underlying cause.
Pursuing the Next Breakthrough in Cancer Cachexia
Cachexia, a complex wasting syndrome, impacts an estimated 9 million people worldwide. Currently, there are no FDA-approved treatments targeting its underlying cause.
Developing a Path Forward in Cancer Cachexia
Across disciplines, therapeutic areas, and even continents, Pfizer scientists have been working to advance understanding of – and potential treatments for – cachexia, a complex metabolic condition associated with certain chronic conditions.
Developing a Path Forward in Cancer Cachexia
Across disciplines, therapeutic areas, and even continents, Pfizer scientists have been working to advance understanding of – and potential treatments for – cachexia, a complex metabolic condition associated with certain chronic conditions.
Bridging Global Gaps in Hemophilia Care
Pfizer is proud of its commitment to advancing hemophilia care for more than 40 years, dating back to the introduction of recombinant therapies.
Bridging Global Gaps in Hemophilia Care
Pfizer is proud of its commitment to advancing hemophilia care for more than 40 years, dating back to the introduction of recombinant therapies.
In Search of a New Hemophilia Treatment
Despite significant advancements in hemophilia treatments over the past several decades, balancing management of the disorder while maintaining regular day-to-day activities remains a challenge.
In Search of a New Hemophilia Treatment
Despite significant advancements in hemophilia treatments over the past several decades, balancing management of the disorder while maintaining regular day-to-day activities remains a challenge.